{"filing":{"accession_number":"0001628280-26-041298","cik":"0001347178","ticker":"VNDA","company_name":"Vanda Pharmaceuticals Inc.","form":"8-K","filing_date":"2026-06-05","report_date":null,"primary_document":"vnda-20260604.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1347178/000162828026041298/vnda-20260604.htm"},"events":[{"id":6640,"run_id":5814,"accession_number":"0001628280-26-041298","anchor_item_number":"5.07","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"summary":"This is a classic Item 5.07 disclosure of shareholder vote results from Vanda's June 4, 2026 annual meeting. The filing reports voting outcomes on four proposals: election of three Class II directors (Dugan, Duncan, Ward), ratification of PricewaterhouseCoopers LLP as auditor, advisory approval of named executive officer compensation, and approval of an amendment to the 2016 Equity Incentive Plan. All proposals passed with substantial majorities, and the detailed vote tallies (for, against, abstaining, broker non-votes) are provided for each matter.","company_name":"Vanda Pharmaceuticals Inc.","ticker":"VNDA","filing_date":"2026-06-05","form":"8-K","submitted_at":null,"items":[{"id":4891,"accession_number":"0001628280-26-041298","item_number":"5.07","item_title":null,"event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This is a classic Item 5.07 disclosure of shareholder vote results from Vanda's June 4, 2026 annual meeting. The filing reports voting outcomes on four proposals: election of three Class II directors (Dugan, Duncan, Ward), ratification of PricewaterhouseCoopers LLP as auditor, advisory approval of named executive officer compensation, and approval of an amendment to the 2016 Equity Incentive Plan. All proposals passed with substantial majorities, and the detailed vote tallies (for, against, abstaining, broker non-votes) are provided for each matter.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-05T20:39:06.007459+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":4891,"accession_number":"0001628280-26-041298","item_number":"5.07","item_title":null,"event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This is a classic Item 5.07 disclosure of shareholder vote results from Vanda's June 4, 2026 annual meeting. The filing reports voting outcomes on four proposals: election of three Class II directors (Dugan, Duncan, Ward), ratification of PricewaterhouseCoopers LLP as auditor, advisory approval of named executive officer compensation, and approval of an amendment to the 2016 Equity Incentive Plan. All proposals passed with substantial majorities, and the detailed vote tallies (for, against, abstaining, broker non-votes) are provided for each matter.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-05T20:39:06.007459+00:00","company_name":"Vanda Pharmaceuticals Inc.","ticker":"VNDA","filing_date":"2026-06-05"}]}